Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetWages, Salaries and Other
Ratios

Ptc Therapeutics (PTCT) EBIAT (2016 - 2025)

Ptc Therapeutics has reported EBIAT over the past 14 years, most recently at -$135.0 million for Q4 2025.

  • Quarterly results put EBIAT at -$135.0 million for Q4 2025, down 104.85% from a year ago — trailing twelve months through Dec 2025 was $682.6 million (up 287.9% YoY), and the annual figure for FY2025 was $682.6 million, up 287.9%.
  • EBIAT for Q4 2025 was -$135.0 million at Ptc Therapeutics, down from $15.9 million in the prior quarter.
  • Over the last five years, EBIAT for PTCT hit a ceiling of $866.6 million in Q1 2025 and a floor of -$198.9 million in Q2 2023.
  • Median EBIAT over the past 5 years was -$127.7 million (2021), compared with a mean of -$69.5 million.
  • Peak annual rise in EBIAT hit 1046.28% in 2025, while the deepest fall reached 104.85% in 2025.
  • Ptc Therapeutics' EBIAT stood at -$143.3 million in 2021, then fell by 19.28% to -$170.9 million in 2022, then grew by 8.83% to -$155.8 million in 2023, then skyrocketed by 57.71% to -$65.9 million in 2024, then crashed by 104.85% to -$135.0 million in 2025.
  • The last three reported values for EBIAT were -$135.0 million (Q4 2025), $15.9 million (Q3 2025), and -$64.8 million (Q2 2025) per Business Quant data.